US Patent

US12303481 — Levodopa dosing regimen

Method of Use · Assigned to Amneal Pharmaceuticals LLC · Expires 2041-12-21 · 16y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for treating Parkinson's disease and related conditions using a specific dosing regimen of levodopa.

USPTO Abstract

The invention is a method for treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1649 — Sinemet Cr
U-1649 — Sinemet Cr
U-1649 — Sinemet Cr
U-1649 — Sinemet Cr

Patent Metadata

Patent number
US12303481
Jurisdiction
US
Classification
Method of Use
Expires
2041-12-21
Drug substance claim
No
Drug product claim
No
Assignee
Amneal Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.